Individualized Therapies for Children with Very High Risk, Relapsed or Refractory Malignancies

Prinses Máxima Centrum voor kinderoncologie0 个研究点目标入组 380 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Relapsed/refractory pediatric cancer, which was established by standard diagnostic methods OR initially diagnosed pediatric cancer patients for whom no standard treatment strategy is available or who have a dismal outcome with current treatment protocols. In the case of very high risk primary disease, the results obtained in the frame of this study may be used at the physician’s discretion to improve a standard treatment strategy and may be applied a at later time point.
•A tissue sample or tumor DNA/RNA as well as normal DNA was obtained as standard of care at diagnosis, resection or at the event of refractory or relapsed disease or is planned with the purpose to confirm the diagnosis or a suspected relapse/refractory disease.
•Life-expectancy of at least 12 weeks.
•Written informed consent according to local law and legislation
•Age <30 years.

•Patients cannot participate in this study if there is no tissue or DNA/RNA available.
•If patients and parents do not want to be informed about detected germline abnormalities

发起方

Prinses Máxima Centrum voor kinderoncologie